148 related articles for article (PubMed ID: 38203596)
1. PIM Kinase Inhibition Attenuates the Malignant Progression of Metastatic Hepatoblastoma.
Julson JR; Quinn CH; Butey S; Erwin MH; Marayati R; Nazam N; Stewart JE; Beierle EA
Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203596
[TBL] [Abstract][Full Text] [Related]
2. PIM kinases mediate resistance to cisplatin chemotherapy in hepatoblastoma.
Marayati R; Stafman LL; Williams AP; Bownes LV; Quinn CH; Aye JM; Stewart JE; Yoon KJ; Anderson JC; Willey CD; Beierle EA
Sci Rep; 2021 Mar; 11(1):5984. PubMed ID: 33727604
[TBL] [Abstract][Full Text] [Related]
3. Targeting PIM kinase as a therapeutic strategy in human hepatoblastoma.
Stafman LL; Mruthyunjayappa S; Waters AM; Garner EF; Aye JM; Stewart JE; Yoon KJ; Whelan K; Mroczek-Musulman E; Beierle EA
Oncotarget; 2018 Apr; 9(32):22665-22679. PubMed ID: 29854306
[TBL] [Abstract][Full Text] [Related]
4. Pan-Pim Kinase Inhibitor AZD1208 Suppresses Tumor Growth and Synergistically Interacts with Akt Inhibition in Gastric Cancer Cells.
Lee M; Lee KH; Min A; Kim J; Kim S; Jang H; Lim JM; Kim SH; Ha DH; Jeong WJ; Suh KJ; Yang YW; Kim TY; Oh DY; Bang YJ; Im SA
Cancer Res Treat; 2019 Apr; 51(2):451-463. PubMed ID: 29879757
[TBL] [Abstract][Full Text] [Related]
5. AZD1208, a Pan-Pim Kinase Inhibitor, Has Anti-Growth Effect on 93T449 Human Liposarcoma Cells via Control of the Expression and Phosphorylation of Pim-3, mTOR, 4EBP-1, S6, STAT-3 and AMPK.
Yadav AK; Kumar V; Bailey DB; Jang BC
Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30654529
[TBL] [Abstract][Full Text] [Related]
6. Protein profiling identifies mTOR pathway modulation and cytostatic effects of Pim kinase inhibitor, AZD1208, in acute myeloid leukemia.
Chen LS; Yang JY; Liang H; Cortes JE; Gandhi V
Leuk Lymphoma; 2016 Dec; 57(12):2863-2873. PubMed ID: 27054578
[TBL] [Abstract][Full Text] [Related]
7. PIM447 inhibits oncogenesis and potentiates cisplatin effects in hepatoblastoma.
Wadhwani N; Markert HR; Marayati R; Bownes LV; Quinn CH; Aye JM; Stewart JE; Yoon KJ; Beierle EA
J Pediatr Surg; 2021 Jun; 56(6):1157-1164. PubMed ID: 33762119
[TBL] [Abstract][Full Text] [Related]
8. PIM Kinase Inhibition Sensitizes Neuroblastoma to Doxorubicin.
Julson JR; Quinn CH; Nazam N; Bownes LV; Stewart JE; Beierle EA
J Pediatr Surg; 2024 Mar; ():. PubMed ID: 38570263
[TBL] [Abstract][Full Text] [Related]
9. AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia.
Keeton EK; McEachern K; Dillman KS; Palakurthi S; Cao Y; Grondine MR; Kaur S; Wang S; Chen Y; Wu A; Shen M; Gibbons FD; Lamb ML; Zheng X; Stone RM; Deangelo DJ; Platanias LC; Dakin LA; Chen H; Lyne PD; Huszar D
Blood; 2014 Feb; 123(6):905-13. PubMed ID: 24363397
[TBL] [Abstract][Full Text] [Related]
10. The novel combination of dual mTOR inhibitor AZD2014 and pan-PIM inhibitor AZD1208 inhibits growth in acute myeloid leukemia via HSF pathway suppression.
Harada M; Benito J; Yamamoto S; Kaur S; Arslan D; Ramirez S; Jacamo R; Platanias L; Matsushita H; Fujimura T; Kazuno S; Kojima K; Tabe Y; Konopleva M
Oncotarget; 2015 Nov; 6(35):37930-47. PubMed ID: 26473447
[TBL] [Abstract][Full Text] [Related]
11. Targeting PIM Kinases Affects Maintenance of CD133 Tumor Cell Population in Hepatoblastoma.
Stafman LL; Williams AP; Garner EF; Aye JM; Stewart JE; Yoon KJ; Whelan K; Beierle EA
Transl Oncol; 2019 Feb; 12(2):200-208. PubMed ID: 30412911
[TBL] [Abstract][Full Text] [Related]
12. PIM kinase inhibitor AZD1208 for treatment of MYC-driven prostate cancer.
Kirschner AN; Wang J; van der Meer R; Anderson PD; Franco-Coronel OE; Kushner MH; Everett JH; Hameed O; Keeton EK; Ahdesmaki M; Grosskurth SE; Huszar D; Abdulkadir SA
J Natl Cancer Inst; 2015 Feb; 107(2):. PubMed ID: 25505253
[TBL] [Abstract][Full Text] [Related]
13. The PIM inhibitor AZD1208 synergizes with ruxolitinib to induce apoptosis of ruxolitinib sensitive and resistant JAK2-V617F-driven cells and inhibit colony formation of primary MPN cells.
Mazzacurati L; Lambert QT; Pradhan A; Griner LN; Huszar D; Reuther GW
Oncotarget; 2015 Nov; 6(37):40141-57. PubMed ID: 26472029
[TBL] [Abstract][Full Text] [Related]
14. PIM kinase inhibitor AZD1208 in conjunction with Th1 cytokines potentiate death of breast cancer cellsin vitrowhile also maximizing suppression of tumor growthin vivo when combined with immunotherapy.
Anwar A; Lepore C; Czerniecki BJ; Koski GK; Showalter LE
Cell Immunol; 2024; 397-398():104805. PubMed ID: 38244265
[TBL] [Abstract][Full Text] [Related]
15. Targeting PIM Kinase with PD1 Inhibition Improves Immunotherapeutic Antitumor T-cell Response.
Chatterjee S; Chakraborty P; Daenthanasanmak A; Iamsawat S; Andrejeva G; Luevano LA; Wolf M; Baliga U; Krieg C; Beeson CC; Mehrotra M; Hill EG; Rathmell JC; Yu XZ; Kraft AS; Mehrotra S
Clin Cancer Res; 2019 Feb; 25(3):1036-1049. PubMed ID: 30327305
[TBL] [Abstract][Full Text] [Related]
16. New Mechanistic Insight on the PIM-1 Kinase Inhibitor AZD1208 Using Multidrug Resistant Human Erythroleukemia Cell Lines and Molecular Docking Simulations.
Marques MB; González-Durruthy M; da Silva Nornberg BF; Oliveira BR; Almeida DV; de Souza Votto AP; Marins LF
Curr Top Med Chem; 2019; 19(11):914-926. PubMed ID: 31072293
[TBL] [Abstract][Full Text] [Related]
17. PIM3 kinase promotes tumor metastasis in hepatoblastoma by upregulating cell surface expression of chemokine receptor cxcr4.
Marayati R; Julson J; Bownes LV; Quinn CH; Stafman LL; Beierle AM; Markert HR; Hutchins SC; Stewart JE; Crossman DK; Hjelmeland AB; Mroczek-Musulman E; Beierle EA
Clin Exp Metastasis; 2022 Dec; 39(6):899-912. PubMed ID: 36315303
[TBL] [Abstract][Full Text] [Related]
18. AZD1208, a pan-Pim kinase inhibitor, inhibits adipogenesis and induces lipolysis in 3T3-L1 adipocytes.
Park YK; Obiang-Obounou BW; Lee KB; Choi JS; Jang BC
J Cell Mol Med; 2018 Apr; 22(4):2488-2497. PubMed ID: 29441719
[TBL] [Abstract][Full Text] [Related]
19. Insights into the Interaction Mechanisms of the Proviral Integration Site of Moloney Murine Leukemia Virus (Pim) Kinases with Pan-Pim Inhibitors PIM447 and AZD1208: A Molecular Dynamics Simulation and MM/GBSA Calculation Study.
Chen Q; Wang Y; Shi S; Li K; Zhang L; Gao J
Int J Mol Sci; 2019 Oct; 20(21):. PubMed ID: 31671637
[TBL] [Abstract][Full Text] [Related]
20. Targeting of glioblastoma cell lines and glioma stem cells by combined PIM kinase and PI3K-p110α inhibition.
Iqbal A; Eckerdt F; Bell J; Nakano I; Giles FJ; Cheng SY; Lulla RR; Goldman S; Platanias LC
Oncotarget; 2016 May; 7(22):33192-201. PubMed ID: 27120806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]